Working… Menu

TARA Working Prototype [Version 2]: Feasibility Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04320524
Recruitment Status : Withdrawn (Due to Covid, the study could not be initiated as planned.)
First Posted : March 25, 2020
Last Update Posted : November 23, 2020
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:

TARA is a Digital Behaviour Change Intervention (DBCI) for Individuals with COPD (IwCOPD), which has been designed using a Human-Centred Design (HCD) methodology. HCD involves, among other elements, members of the target audience in evaluations at multiple stages within the design process.

This feasibility study is primarily designed to assess the acceptability of the DBCI test asset to the target audience. Acceptability as defined for the purpose of this study includes usability of the system, and perceived value and desirability to the end-user audience. As such, engagement in this context is deemed to mean the degree to which the test asset provides a usable, acceptable, desirable and valuable experience to its users during a time-limited trial.

Condition or disease Intervention/treatment Phase
Pulmonary Disease, Chronic Obstructive Device: Technology-Assisted Respimat Adherence Digital Behaviour Change Intervention Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: Mixed Methods (Quantitative, Qualitative) Feasability Study Assessing Engagement With the TARA Working Prototype [Version 2] (a Digital Behaviour Change Intervention, DBCI) and Effects of TARA on Behavioural Targets and Medication Adherence in Individuals With COPD
Estimated Study Start Date : February 17, 2021
Estimated Primary Completion Date : July 12, 2021
Estimated Study Completion Date : September 6, 2021

Arm Intervention/treatment
Experimental: All subjects Device: Technology-Assisted Respimat Adherence Digital Behaviour Change Intervention
3 weeks

Primary Outcome Measures :
  1. Patient interaction with TARA (engagement via usage data) [ Time Frame: up to 3 weeks ]
    Data sourced from individual and amalgamated usage analytics. Data points collected from TARA Patient database / usage analytics, recording the completion with time and date stamps by the users of key sections of the TARA program. An overall score for perceived ease-of-use will be generated using the System Usability Scale (SUS) participant questionnaire

  2. Assessment of usability issues [ Time Frame: up to 3 weeks ]

    Qualitative assessment of participant's feedback on any usability issues, areas of confusion or lack of clarity whilst using TARA working prototype (version 2).

    Data sourced from participant's reports, emails and exit interviews.

  3. Assessment of motivation and perception [ Time Frame: up to 3 weeks ]
    Qualitative assessment of data sourced through the prototype and via discussion in the exit interview

Secondary Outcome Measures :
  1. Percent of individuals with COPD who achieve improvements in intention (Readiness for Change) measured by the Readiness for Change Questionnaire [ Time Frame: up to 3 weeks ]
  2. Percent of individuals with COPD who achieve improvements in autonomous motivation measured by the Treatment Self-Regulation Questionnaire (TSRQ) [ Time Frame: up to 3 weeks ]
  3. Percent of individuals with COPD who achieve confidence measured by the Perceived Competence Scale; PCS) [ Time Frame: up to 3 weeks ]
  4. Percent of participants who increased adherence to once daily inhaled medication, based on Test of Adherence to Inhalers (TAI) Questionnaire [ Time Frame: up to 3 weeks ]
  5. Percent of participants who report increases in adherence to once daily inhaled medication, based on study-specific medication adherence question [ Time Frame: up to 3 weeks ]
    Medication adherence question: "During the last 7 days, how many times did you forget to take your daily inhaler ?"

  6. Percent of participants who report increases in adherence to once daily inhaled medication, based on prescription re-fill confirmation [ Time Frame: up to 3 weeks ]
  7. Percent of participants who report increases in adherence to once daily inhaled medication, based on TARA daily check-in data. [ Time Frame: up to 3 weeks ]
  8. Percent of study participants who report a reduction in COPD symptoms measured via the COPD Assessment test (CAT) [ Time Frame: up to 3 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed and dated written electronic informed consent (e-consent) in accordance with ICH-GCP and local legislation prior to admission to the study
  • Male or female patients
  • All patients must have a self-reported confirmation of a physician diagnosis of COPD (or chronic bronchitis or emphysema)
  • Age ≥ 40 years
  • Patients must be current or ex-smokers
  • Modified Medical Research Council (mMRC) Score ≥ 2 (i.e. evidence of activity-related breathlessness)
  • Patients must have a current prescription for either Spiriva Respimat or Stiolto Respimat in keeping with their approved labels as well as a short-acting bronchodilator ("rescue medication") for at least 3 months prior to study enrolment
  • Participants must be willing to use a smart watch and be willing to complete all data collection requirements (within TARA plus phone interview plus on-line questionnaires)
  • Patients must confirm that their treating physician has been informed about their participation in the study (prior to TARA log-in)
  • Fluency in written English
  • Currently residing in US (for duration of study)
  • Participants should be not fully adherent to once daily inhaled COPD medication (as measured with a score of 2 or greater on a protocol-specific participant self-assessment scale of forgetting to take the medication in the last 7 days)
  • Access to (and comfort with) a digital device (Desktop; Laptop; Tablet), with updated Firefox or Chrome browsers installed (or willing to download up-to-date version for the study), and daily home access to internet
  • Need to have personal e-mail account that is used daily

Key Exclusion Criteria:

  • Patients with asthma
  • Patient with a worsening COPD episode requiring medical intervention within 4 weeks of enrolment
  • Patients who have completed a pulmonary rehabilitation (PR) program in the 6 months prior to enrolment or patients who are currently in a PR program (rationale: PR programs typically include a self-management component which may interfere with study objectives)
  • Planned vacation period during the study period that requires overnight stays away from home
  • Major surgery performed within 6 weeks prior to enrolment or planned within 2 months after enrolment, e.g. hip replacement
  • Patients prescribed inhaled COPD medications other than Spiriva Respimat plus albuterol or Stiolto Respimat plus albuterol
  • Previous enrolment in study 352.2133
  • Previous enrolment in this study Further exclusion criteria apply
Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT04320524    
Other Study ID Numbers: 0352-2134
First Posted: March 25, 2020    Key Record Dates
Last Update Posted: November 23, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).For more details refer to:

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive